A Safety and Cognitive Function Study of EVP-6124 Versus Placebo in Subjects With Nicotine Dependence
Status:
Terminated
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the initial evidence for efficacy of the investigational
medicine, EVP-6124, to improve smoking cessation outcomes with and without a standard taper
of nicotine replacement therapy (NRT) in healthy nicotine dependent smokers
Phase:
Phase 2
Details
Lead Sponsor:
A. Eden Evins
Collaborators:
FORUM Pharmaceuticals Inc National Institute on Drug Abuse (NIDA)